In a Maternity Care Crisis, CMS Undermines Efforts To Modernize Care
CMS has introduced uncertainty about whether Medicare will participate in that modernization or preserve the old system under a different name. The consequences extend far beyond billing
FDA Alignment Is a Starting Point, Not a Rare Disease Strategy for the European Market
For US biotech companies developing rare disease therapies, decisions about clinical evidence, patient populations and regulatory advice can have consequences in Europe long before a marketing application is submitted.
CareValidate Launches Expanded HRT Offering
CareValidate expanded its HRT offering for telehealth companies, combining hormone therapy with provider access, pharmacy services and AI-powered care coordination.
Lycia Lands a $317M IPO for Inflammation Drugs Based on Nobel Prize-Winning Science
Lycia Therapeutics’ protein-degrading drugs are based on the research of Carolyn Bertozzi, a Stanford chemistry professor and Nobel laureate. Lycia’s lead drug candidate is in development for food allergy, where it could compete against the blockbuster Roche drug Xolair.
Congress’s Patient Matching Fix Won’t Work — Here’s What Would
The MATCH IT Act aims to reduce patient matching errors. But a model used by vital records systems could provide a better solution.